EVLO News and Press, Evelo Biosciences Inc. From 02/27/23

– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns – – Dosing in EDP2939 Phase 2 trial in patients with moderate psoriasis has been initiated – – EDP2939 Phase 2 data in psoriasis anti...

Clinical-stage biotech Evelo Biosciences ( NASDAQ: EVLO ) lost ~23% pre-market Wednesday after announcing that its atopic dermatitis candidate EDP1815 failed to meet the main goal in a Phase 2 trial. The company also announced that it implemented cost-saving initiatives, including wor...

– Data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint; unusually high placebo response rate observed – – Clear path to registration trials for EDP1815 in psoriasis base d on recently completed interactions with F...

Horizon Technology Finance Provides Fourth Quarter 2022 Portfolio Update PR Newswire - Horizon Platform Originates $114 Million of New Loans in Q4, Including $104 Million of New Loans for HRZN - - HRZN Grows Loan Portfolio by $262 Million in 2022 - - ...

CAMBRIDGE, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced it has entered into a senior secured loan agreem...

Peer-reviewed article explains the immunology of the small intestinal axis Company to hold a virtual Science Symposium on Wednesday, November 30, 2022, at 8:00am ET CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotec...

Evelo Biosciences press release ( NASDAQ: EVLO ): Q3 GAAP EPS of -$0.28 in-line. As of September 30, 2022, cash and cash equivalents were $69.1M, as compared to cash and cash equivalents of $68.4M as of December 31, 2021 For further details see: Evelo Biosciences...

- Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 - - Phase 2 data for first extracellular vesicle product candidate EDP2939 in psoriasis anticipated in 2H 2023 ȁ...

CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that Simba Gill, Ph.D., Chief Executive O...

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today presented biomarker data demonstrating the broad a...